Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Century Therapeutics

Main focus: Next-generation cell therapies for the treatment of cancer

Company stage: Pre-clinical

Diseases (gene editing): Cancer

Genome editing tool: CRISPR-MAD7

Funding stage: Public (NASDAQ:IPSC)

Location: Philadelphia, PA, USA



Gene-editing partnerships: Inscripta, Bristol Myers Squibb

Century Therapeutics is developing next-generation cell-based therapies to treat haematological and solid tumours. The company uses its iPSC platform to generate allogeneic, iPSC-derived natural killer (NK) and T cell products. The company uses the CRISPR-MAD7 system to introduce multiple knock-outs to its cellular products, in order to avoid host-versus-graft reactions and increase persistence and durability.


HashtagCentury Therapeutics

Company: Century Therapeutics
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine